---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-010085"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:49:42.672459+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar CMO Mary Tagliaferri resigns; Brian Kotzin named interim CMO

## Summary
- Mary Tagliaferri resigned as SVP and CMO effective Feb 4, 2025, for personal reasons; no disagreement with company.
- Brian Kotzin, MD, appointed interim CMO; he previously served as strategic advisor for rezpegaldesleukin program since April 2023.
- Kotzin has over 40 years immunology experience; was VP at Amgen and held academic positions; will assist search for permanent CMO.
- Kotzin currently serves on boards of Argenx SE, Biora Therapeutics, and Genascence Corporation.

## SEC filing metadata
- accession: 0001213900-25-010085
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025010085/0001213900-25-010085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025010085/ea0229922-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-010085
- JSON: https://secwatch.observer/filing/0001213900-25-010085.json
- Plain text: https://secwatch.observer/filing/0001213900-25-010085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.